---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025474"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-08-03T21:11:51+00:00"
generated_at: "2026-08-03T21:14:12.462857+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech raises ~$9.3M in public offering of common stock and warrants

## Summary
- Gross proceeds of ~$9.3M from sale of 12.4M shares and warrants at $0.75 per unit.
- Warrants exercisable at $0.75 for five years; pre-funded warrants at $0.001.
- Proceeds to fund Annamycin clinical development and working capital.
- Lock-up agreements for officers/directors for 60 days; 45-day ban on further equity issuances.
- Placement agent fees: 6.5% to Roth Capital, 1% to Maxim Group.

## SEC filing metadata
- accession: 0001437749-26-025474
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-08-03T21:11:51+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926025474/0001437749-26-025474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926025474/mbrx20260803_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025474
- JSON: https://secwatch.observer/filing/0001437749-26-025474.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.